-
-
-
-
-
-
-
FDA issues psychedelic therapy guidance as Clearmind notes federal push
-
-
-
-
-
-
-
Clearmind reports improved nasal retention for its MEAI drug formulation
-
-
-
-
-
-
-
Moderna doses first patient in Phase 1 trial for mRNA-4200 cancer therapy
-
-
-
-
-
-
-
G50 reports Phase 2 gallium test results at Arizona project
-
-
-
-
-
-
-
aTyr Pharma to present efzofitimod subgroup data at WASOG 2026
-
-
-
-
-
-
-
Merck to present HIV pipeline data at AIDS 2026 conference
-
-
-
-
-
-
-
Veradermics to host call on Phase 2 hair loss drug trial results
-
76,368 total articles have been posted to this category.
Sign-up to StreetInsider.com Premium
to see all today's market moving FDA reports.

